https://www.cohenveteransbioscience.org/wp-content/themes/cvb-theme/assets/img/icon-news-card.png
Chief Medical Officer Dr. Allyson Gage Interviewed by Applied Clinical Trials
Hear from CVB's Chief Medical Officer about the benefits of adaptive platform trial design.
In a recent interview with Applied Clinical Trials, our Chief Medical Officer Dr. Allyson Gage discussed the benefits of adaptive platform trial design, especially for diseases where the underlying biology and mechanism of disease is undetermined.
Read the article “What You Need to Know About Adaptive Platform Design” to learn more.
Share this article:
More from CVB
https://www.cohenveteransbioscience.org/wp-content/uploads/2024/01/cv.webp
Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder
https://www.cohenveteransbioscience.org/wp-content/uploads/2022/11/bigstock-Dna-With-Unique-Connection-155670029.jpg
New meta-analysis builds upon PTSD genetics research, providing a foundation for the development of precision therapies
https://www.cohenveteransbioscience.org/wp-content/uploads/2022/06/CVB-Circuit-Newsletter-Header.png
The Circuit – April 2024
About Cohen Veterans Bioscience (CVB)
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
